Fan Jian-Bing, Hu Sean X, Craumer William C, Barker David L
Illumina, San Diego, CA 92121, USA.
Biotechniques. 2005 Oct;39(4):583-8.
A "one-size-fits-all" approach continues to characterize today's healthcare paradigm. But emergent rules, information, genomics tools, and economics are driving a fundamental and inevitable shift to a more personalized world of medicine. In this new world, the interests of insurers, regulators, suppliers, healthcare providers, and most important, patients, will have converged. The new goal will be the right treatment for the right individual at the right time. In this world, personalized medicine, through pharmacogenomics (PGx), will be the new healthcare paradigm. We will briefly examine healthcare trends and current opportunities for PGx development. We will then demonstrate how microarray technologies-among them bead-based approaches-have emerged as a key enabler for bringing home the promise of PGx.
“一刀切”的方法仍然是当今医疗保健模式的特点。但新出现的规则、信息、基因组学工具和经济学正在推动向更加个性化的医学世界发生根本性且不可避免的转变。在这个新的世界里，保险公司、监管机构、供应商、医疗保健提供者，以及最重要的患者的利益将趋于一致。新的目标将是在正确的时间为正确的个体提供正确的治疗。在这个世界里，通过药物基因组学（PGx）实现的个性化医疗将成为新的医疗保健模式。我们将简要审视医疗保健趋势以及当前PGx发展的机遇。然后我们将展示微阵列技术——其中包括基于微珠的方法——是如何成为实现PGx前景的关键推动因素的。
